32 results about "Pleural mesothelioma" patented technology

The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression / regression also are provided.

The influence of TF, endothelial cell protein C receptor (EPCR) and protease activated receptor-1 (PAR1) on tumor growth of malignant pleural mesothelioma (MPM) is disclosed. MPM cells that lack or express TF, EPCR or PAR1 and a murine orthotopic model of MPM led to the discovery that intrapleural administration into nude mice of REN MPM cells expressing TF and PAR1 but lacking EPCR and PAR2 generated large pleural cavity tumors. Suppression of TF or PAR1 expression markedly reduced tumor growth. Overexpression of TF in non-aggressive MPM cells expressing EPCR and PAR1 but exhibiting minimal levels of TF failed to alter their tumorigenicity. Introduction of EPCR expression in aggressive MPM cells attenuated tumor growth whereas EPCR silencing in non-aggressive MPM cells overexpressing TF increased tumorigenicity of non-aggressive cells. Expression of EPCR by MPM cells suppresses tumor growth and treats MPM.

The present invention provides a method for testing mesothelioma comprising a step of determining a concentration of a human periostin protein in at least one type of sample of blood or pleural fluid of a subject. In the step of determining the concentration of human periostin protein, an antibody directed against human periostin protein may be used. The present invention further provides a kit for diagnosing mesothelioma, said kit comprising an antibody directed against human periostin protein. In the kit for diagnosing mesothelioma, the antibody directed against a human periostin protein may be an antibody that binds to a polypeptide consisting of an amino acid sequence set out in SE ID NO: 2.

The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.

To develop a simple, low-cost and highly reliable testing method for mesothelioma, and a kit used for said testing method. The present invention provides a testing method for mesothelioma comprising a step in which the concentration of human periostin protein is measured in at least one type of sample from among samples of the blood or pleural fluid of a subject. The step in which the concentration of human periostin protein is measured may use an antibody directed against human periostin protein. The present invention further provides a kit for diagnosing mesothelioma, said kit including the antibody directed against human periostin protein. In one kit for diagnosing mesothelioma, the diagnosis of mesothelioma determines if a subject that may have mesothelioma has mesothelioma or is healthy. In another kit for diagnosing mesothelioma, the diagnosis of mesothelioma determines if a subject that may have mesothelioma has mesothelioma or has a respiratory illness other than mesothelioma.

An object of the present invention is to develop a simple, inexpensive, and highly reliable method for examining mesothelioma, and a kit used in the method. As a solution to the problem, the present invention provides a method for examining mesothelioma, comprising the step of measuring the concentration of human periostin protein in at least one sample of blood or pleural fluid of a subject. In some cases, the step of measuring the concentration of the human periostin protein uses an antibody against the human periostin protein. The present invention provides a kit for the diagnosis of mesothelioma, comprising an antibody against human periostin protein. In the kit for diagnosing mesothelioma of the present invention, the diagnosis of mesothelioma may be to determine whether a subject who may have mesothelioma is a mesothelioma patient or a normal person. In the kit for diagnosing mesothelioma of the present invention, the diagnosis of mesothelioma may be to determine whether a subject who may suffer from mesothelioma is a patient with mesothelioma or a respiratory organ disease other than mesothelioma of patients.

The invention provides a treatment of mesothelioma, especially malignant pleural mesothelioma, using an estrogen receptor β subtype (ERβ) agonist, wherein the treatment comprises administering the ERβ agonist to the patient, and then after a time, t, of up to 24 hours; administering a platinum-containing anti-cancer drug to the patient. The invention also provides an ERβ agonist and a platinum-containing anti-cancer drug for use in the treatment of mesothelioma in a patient, wherein the treatment comprises administering the ERβ agonist to the patient, and then after a time, t, of up to 24 hours, administering the platinum-containing anti-cancer drug to the patient; and a kit comprising a platinum-containing anti-cancer drug and an ERβ agonist.

The invention discloses a Mesothelin-targeted replication-defective recombinant lentivirus CAR-T transgenic carrier which comprises a pronucleus replicon pUC Ori sequence for plasmid replication, an amicillin resistance gene AmpR containing sequence for mass amplification of target strain, virus replicon SV40Ori sequence for enhancing replication in eukaryocyte, a lentivirus packaging cis-element for lentivirus packaging, a ZsGreen1 green fluorescent protein for green fluorescence expression of eukaryocyte, an IRES ribosome combination sequence for joint transcriptional expression of protein, a human EF1(alpha) promoter for the eukaryotic transcription of chimeric antigen receptor gene, a chimeric antigen receptor for forming a second-generation CAR or third-generation CAR integrating identification, transfer and start, and an eWPRE element for improving the transgenic expression efficiency. Moreover, the invention also discloses an establishment method and application of the carrier. In the invention, the secretion of cell factors and the in-vitro killing effect of CAR-T cells can be remarkably enhanced, and the effect of clinical treatment of malignant pleural mesothelioma and pancreatic cancer is outstanding.

An application of Aidi preparation in the preparation of anti-malignant pleural mesothelioma medicines. The Aidi preparation disclosed by the invention is composed of mylabris, ginseng, astragalus and Acanthopanax four herbs; the Aidi preparation of the present invention has stronger The anti-malignant pleural mesothelioma has significant drug efficacy, less side effects, and safer clinical medication, which provides a new therapeutic approach for the treatment of malignant pleural mesothelioma and expands the clinical application of Aidi preparations.

The present invention provides conjugates of cytokines and targeting peptides that is able to bind to a receptor expressed on tumor-associated vessels or to a component of the extracellular matrix associated to the tumor vessels, for treatment of malignant pleural mesothelioma. In particular, the invention provides conjugates comprising the cytokine TNF linked to a peptide containing the NGR motif. The invention further provides pharmaceutical compositions comprising such conjugate and pharmaceutical formulations comprising conjugates dissolved in appropriate buffers.

The present invention provides diagnostic methods based on the levels of osteopontin.

The present invention relates to a liquid pharmaceutical composition suitable for parenteral administration comprising:a) pemetrexed diacid;b) at least one organic amine;c) at least one antioxidant;d) 10-200 mg / ml of propylene glycol; ande) one or more parenteral solvents,wherein the preparation thereof is conducted in an atmosphere of inert gas and wherein the organic amine(s) is present in an amount sufficient to reach a pH of the composition in the range from 8.3 to 9.1The invention further relates to the use of said liquid pharmaceutical composition as medicament in the treatment of malignant pleural mesothelioma and non-small cell lung cancer.

The present invention relates to a stable liquid pharmaceutical composition of pemetrexed for parenteral administration. The invention provides composition comprising pemetrexed diacid, an organic amine and cyclodextrin. The composition may further comprise an inert gas. The composition can be ready to use infusion solution of pemetrexed diacid or liquid concentrate formulation to be diluted before administration to the patient. The present invention further relates to a process for manufacturing the compositions as well as use of the compositions of the invention for the treatment of malignant pleural mesothelioma and non-small cell lung cancer.